AtriCure price target lowered to $74 from $81 at Canaccord

Canaccord analyst William Plovanic lowered the firm’s price target on AtriCure to $74 from $81 and keeps a Buy rating on the shares. The analyst said the company still believes that the large opportunity for EPi-Sense remains but more near-term work needs to be completed to overcome some of the structural challenges that are creating friction to adoption.